0.3257

0.28% 0.0057

Fibrogen Inc (FGEN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché FGEN Giù? Forum Previsione

Precedente Chiudi:

$0.32

Aprire:

$0.3104

Volume 24 ore:

365.09K

Relative Volume:

0.12

Capitalizzazione di mercato:

$28.89M

Reddito:

$147.75M

Utile/perdita netta:

$-284.23M

Rapporto P/E:

-0.1112

EPS:

-2.93

Flusso di cassa netto:

$-317.54M

1 W Prestazione:

+12.09%

1M Prestazione:

-6.33%

6M Prestazione:

+4.19%

1 anno Prestazione:

-68.54%

Intervallo 1D:

$0.3064

$0.3316

Intervallo di 1 settimana:

$0.2806

$0.3287

Portata 52W:

$0.18

$1.74

Fibrogen Inc Stock (FGEN) Company Profile

Nome

Fibrogen Inc

Settore

Healthcare (1148)

Industria

Biotechnology (664)

Telefono

415-978-1200

Indirizzo

350 BAY STREET, SAN FRANCISCO, CA

Dipendente

225

Cinguettio

@FibroGenInc

Prossima data di guadagno

2025-03-17

Ultimi documenti SEC

FGEN's Discussions on Twitter

Confronta FGEN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FGEN Fibrogen Inc	0.3257	28.89M	147.75M	-284.23M	-317.54M	-2.93
VRTX Vertex Pharmaceuticals Inc	491.47	125.74B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	595.91	61.57B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	607.39	36.40B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	250.49	30.36B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	248.08	24.89B	3.81B	-644.79M	-669.77M	-6.24

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-08	Downgrade	BofA Securities	Neutral → Underperform
2023-06-26	Downgrade	BofA Securities	Buy → Neutral
2023-06-26	Downgrade	Raymond James	Outperform → Mkt Perform
2023-06-26	Downgrade	Stifel	Buy → Hold
2023-06-26	Downgrade	William Blair	Outperform → Mkt Perform
2023-06-02	Aggiornamento	Stifel	Hold → Buy
2023-01-31	Aggiornamento	William Blair	Mkt Perform → Outperform
2023-01-26	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-01-05	Aggiornamento	BofA Securities	Neutral → Buy
2021-09-22	Downgrade	Goldman	Neutral → Sell
2021-08-20	Aggiornamento	Raymond James	Underperform → Mkt Perform
2021-07-16	Downgrade	BofA Securities	Buy → Neutral
2021-07-16	Downgrade	Stifel	Buy → Hold
2021-04-07	Downgrade	H.C. Wainwright	Buy → Neutral
2021-04-07	Downgrade	Mizuho	Buy → Neutral
2021-03-31	Aggiornamento	BofA Securities	Neutral → Buy
2021-03-02	Downgrade	Jefferies	Buy → Hold
2021-02-01	Iniziato	H.C. Wainwright	Buy
2020-10-26	Iniziato	Raymond James	Underperform
2020-07-10	Ripresa	Stifel	Buy
2020-05-01	Iniziato	Cowen	Market Perform
2020-04-27	Iniziato	BofA/Merrill	Neutral
2019-05-29	Ripresa	Goldman	Neutral
2019-05-10	Downgrade	William Blair	Outperform → Mkt Perform
2019-04-12	Iniziato	Piper Jaffray	Neutral
2019-02-11	Ripresa	Stifel	Buy
2018-12-19	Aggiornamento	Citigroup	Neutral → Buy
2017-08-08	Reiterato	Leerink Partners	Outperform
2017-08-08	Reiterato	Stifel	Buy
2017-07-21	Downgrade	Goldman	Buy → Neutral
2017-07-11	Iniziato	Jefferies	Buy
2016-02-11	Aggiornamento	Credit Suisse	Neutral → Outperform
2016-01-21	Iniziato	Credit Suisse	Neutral
2015-12-04	Iniziato	Citigroup	Buy
2015-09-23	Iniziato	Lake Street	Hold
2015-07-29	Iniziato	Citigroup	Buy
2015-07-20	Aggiornamento	Goldman	Neutral → Buy
2014-12-09	Iniziato	Stifel	Buy

Mostra tutto

Fibrogen Inc Borsa (FGEN) Ultime notizie

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025

Apr 11, 2025

FGEN Stock Price and Chart — NASDAQ:FGEN - TradingView

Apr 11, 2025

Apr 08, 2025

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st

Apr 08, 2025

Apr 02, 2025

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 02, 2025

Apr 01, 2025

William Blair Keeps Their Hold Rating on FibroGen (FGEN) - The Globe and Mail

Apr 01, 2025

Mar 30, 2025

FibroGen extends merger option deadline with Fortis - Investing.com Australia

Mar 30, 2025

Mar 28, 2025

FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com South Africa

Mar 28, 2025

Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail

Mar 28, 2025

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology - The Manila Times

Mar 28, 2025

FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com

Mar 28, 2025

Mar 27, 2025

1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail

Mar 27, 2025

Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia

Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India

Mar 25, 2025

Mar 24, 2025

Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada

Mar 24, 2025

Mar 20, 2025

In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media

Mar 20, 2025

Mar 19, 2025

FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025

FibroGen Full Year 2024 Earnings: Beats Expectations - Yahoo

Mar 19, 2025

Mar 18, 2025